Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA

被引:12
|
作者
Deezagi, A. [1 ]
Ansari-Majd, S. [1 ]
Vaseli-Hagh, N. [1 ]
机构
[1] Natl Inst Genet Engn & Biotechnol, Dept Biochem, Tehran, Iran
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2012年 / 14卷 / 10期
关键词
Vascular endothelial growth factor; siRNA; DU-145 prostate cancer cells; Apoptosis; Cell proliferation; Platting efficiency; IN-VITRO; RNA INTERFERENCE; TYROSINE KINASE; DOWN-REGULATION; VEGF RECEPTORS; TARGETING VEGF; ANGIOGENESIS; EXPRESSION; CARCINOMA; TUMOR;
D O I
10.1007/s12094-012-0868-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor (VEGF) regulates several cell functions including; proliferation, differentiation, permeability, vascular tone, and the production of vasoactive molecules. The purpose of this study was to evaluate the potency of specific short-interfering RNA (siRNA) to suppress human VEGF expression by siRNA and investigate the effects of VEGF down-regulation on the cell proliferation and apoptosis of the human prostate cancer cell lines DU-145. Transfection was performed using X-tremeGENE siRNA transfection reagent. At different time intervals, transfected cells were harvested and total RNA was extracted for RT-PCR. The VEGF content in supernatants were measured by ELISA. Inhibition of cell growth by hVEGF-siRNA was measured by using cell proliferation ELISA BrdU assay. Apoptotic cells were evaluated by using annexin-V-FITC apoptotic detection method. Transfection of hVEGF-siRNA resulted in statistically significant inhibition of hVEGF-mRNA that in turn caused a marked reduction in the expression of hVEGF. The cell growth was assessed every 24 h for 4 days after siRNA treatment resulted in a marked inhibition of cell proliferation as compared to scramble siRNA. The results of apoptosis showed that approximately 15 % of the cells treated with control-siRNA manifested evident apoptotic changes after 24 hpt, whereas DU-145 cells treated with hVEGF-siRNA significantly were positive, that is to say, 53 % at 72 hpt 23.9 +/- A 2.78 % (P < 0.001) and 13 +/- A 1.57 % at 96 hpt. Our findings indicate that siRNA are effective in eliciting the RNAi pathway in cancerous cells and that specific siRNA efficiently down-regulate VEGF expression. They could decrease VEGF production and induce apoptosis, which may also be linked to the inhibition of cancerous cell proliferation. Therefore, it can be concluded that siRNA-mediated suppression of VEGF represents a powerful tool against prostate cancer cell proliferation. VEGF down-regulation exerts a direct anti-apoptotic function in the DU-145 cell lines and promises the development of drugs for cancer therapy.
引用
收藏
页码:791 / 799
页数:9
相关论文
共 50 条
  • [1] Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA
    A. Deezagi
    S. Ansari-Majd
    N. Vaseli-Hagh
    [J]. Clinical and Translational Oncology, 2012, 14 : 791 - 799
  • [2] The vascular endothelial growth factor (VEGF) as an autocrine and resistance factor to apoptosis in human prostate cancer cells(LNCaP)
    Colon, NM
    Buttyan, R
    [J]. MOLECULAR BIOLOGY OF THE CELL, 1999, 10 : 40A - 40A
  • [3] Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer
    Bai, Wen-kun
    Zhang, Wei
    Hu, Bing
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 1267 - 1274
  • [4] Effect of vascular endothelial growth factor and epidermal growth factor on iatrogenic apoptosis in human endothelial cells
    Vinci, MC
    Visentin, B
    Cusinato, F
    Nardelli, GB
    Trevisi, L
    Luciani, S
    [J]. BIOCHEMICAL PHARMACOLOGY, 2004, 67 (02) : 277 - 284
  • [5] Vascular endothelial growth factor in prostate cancer
    Turner, K
    Jones, A
    [J]. UROLOGY, 2000, 56 (01) : 183 - 183
  • [6] Expression of vascular endothelial growth factor receptors in human prostate cancer
    Ferrer, FA
    Miller, LJ
    Lindquist, R
    Kowalczyk, P
    Laudone, VP
    Albertsen, PC
    Kreutzer, DL
    [J]. UROLOGY, 1999, 54 (03) : 567 - 572
  • [7] Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells
    Ferrer, FA
    Miller, LJ
    Andrawis, RI
    Kurtzman, SH
    Albertsen, PC
    Laudone, VP
    Kreutzer, DL
    [J]. JOURNAL OF UROLOGY, 1997, 157 (06): : 2329 - 2333
  • [8] Role of vascular endothelial growth factor in prostate cancer
    Delongchamps, Nicolas Barry
    Peyromaure, Michael
    Dinh-Xuan, Anh Tuan
    [J]. UROLOGY, 2006, 68 (02) : 244 - 248
  • [9] Regulation of vascular endothelial growth factor in prostate cancer
    de Brot, Simone
    Ntekim, Atara
    Cardenas, Ryan
    James, Victoria
    Allegrucci, Cinzia
    Heery, David M.
    Bates, David O.
    Odum, Niels
    Persson, Jenny L.
    Mongan, Nigel P.
    [J]. ENDOCRINE-RELATED CANCER, 2015, 22 (03) : R107 - R123
  • [10] Lipopolysaccharide-induced apoptosis of endothelial cells and its inhibition by vascular endothelial growth factor
    Munshi, N
    Fernandis, AZ
    Cherla, RP
    Park, IW
    Ganju, RK
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (11): : 5860 - 5866